Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 10,355 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Extreme Prematurity, Enteral Nutrition, Bronchopulmonary Dysplasia
Interventions: High-energy group, Standard-energy group; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 3 Days
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Skin Laxity
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year to 16 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: thioureidobutyronitrile; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 13 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more

Conditions: Pectus Excavatum, Pain, Postoperative
Interventions: Multimodal Erector spinae catheter protocol; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Thyroid Eye Disease
Interventions: Veligrotug, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more

Conditions: Atopic Dermatitis
Interventions: GIA632, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fremont, California • Rockville, Maryland • Hoboken, New Jersey

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions: NHS7108, Zenpep®; Drug
Lead sponsor: Aimmune Nestlé Health Science US R&D, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Polycystic Ovary Syndrome
Interventions: Salsalate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lymphatic Malformations
Interventions: Selenium; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 14 Years to 30 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Smith-Lemli-Opitz Syndrome
Interventions: Simvastatin Susp., OraPlus; Drug
Lead sponsor: Forbes Porter, M.D.; NIH
Eligibility: 4 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: cytarabine, daunorubicin hydrochloride, etoposide, tipifarnib, chemotherapy, enzyme inhibitor therapy, high-dose chemotherapy; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
Interventions: ABO-102; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cerebral Palsy, Spina Bifida
Interventions: Virtual Peer Health Coaching; Behavioral
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Vascular Ehlers-Danlos Syndrome
Interventions: Heartmath Intervention, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Basal Cell Nevus Syndrome, Gorlin's Syndrome
Interventions: Vismodegib, Aminolevulinic acid %20 topical solution; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Oakland, California • New York, New York

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Mucopolysaccharidosis I (MPS I)
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 1,406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 53
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 44 more

Conditions: Alport Syndrome
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 1 Year and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Andersen-Tawil Syndrome
Interventions: Potassium, Acetazolamide; Dietary Supplement · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants

Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and Neck

Weight-based Dosing in Hemophilia A

Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Pectus ESC Outcomes and Comparative Effectiveness Study

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Selenium in the Treatment of Complicated Lymphatic Malformations

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

Virtual Peer Health Coaching for Adolescents With Disabilities

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Mucopolysaccharidosis I (MPS I) Registry

Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome